

Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/518,501
Filing Date	March 3, 2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	T. McKenzie E. Sackey
Attorney Docket Number	2358.0010002/RWE/CJW (MTI-013)

Sheet 1 of 1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

561117_1.DOC

Examiner Signature		Date Considered	9/7/06
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (07-05)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

1 of 1

Complete if Known

Application Number	09/518,501
Filing Date	March 3, 2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	T. McKenzie E. Sackey
Attorney Docket Number	2358.0010002/RWE/CJW (MTI-013)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
ES	C128	ARNÉR, E.S.J. and ERIKSSON, S., "Mammalian Deoxyribonucleoside Kinases," <i>Pharmac. Ther.</i> 67(2): 155-186, Elsevier Science Ltd. (1995).	
ES	C129	ELLIOTT, R.L. et al., "Synthesis and Biological Evaluation of Phosphonamidate Peptide Inhibitors of Enkephalinase and Angiotensin-Converting Enzyme," <i>J. Med. Chem.</i> 28: 1208-1216, American Chemical Society (1985).	
ES	C130	ERION, M.D. et al., "HepDirect Prodrugs for Targeting Nucleotide-Based Antiviral Drugs to the Liver," <i>Current Opinion in Investigational Drugs</i> 7(2): 109-117, The Thomson Corporation (2006).	
ES	C131	FREEMAN, S. and ROSS, K., "Prodrug Design for Phosphates and Phosphonates," <i>Progress in Medicinal Chemistry</i> 34: 111-147, Elsevier Science B.V. (1997).	
ES	C132	GORENSTEIN, D.G. et al., "Stereoelectronic Effects in the Reactions of Epimeric 2-Aryloxy-2-oxy-1,3,2-dioxaphosphorinanes and Oxazaphosphorinanes," <i>J. Am. Chem. Soc.</i> 102: 5077-5081, American Chemical Society (1980).	
ES	C133	HULST, R. et al., "A New ³¹ P NMR Method for the Enantiomeric Excess Determination of Alcohols, Amines and Amino Acid Esters," <i>Tetrahedron Letters</i> 34(8): 1339-1342, Pergamon Press Ltd. (1993).	
ES	C134	LOREY, M. and MEIER, C., "A New Cyclic Phosphoramidate D4T Prodrug Approach CycloAmb-D4T-Phosphoramidates," <i>Nucleosides & Nucleotides</i> 18(4&5): 947-948, Marcel Dekker, Inc. (1999).	
ES	C135	MERCKLING, F.A. and RÜEDI, P., "Diasteroselectivity in Nucleophilic Displacement Reactions at Phosphorus; Isolation and Characterization of a Pentacoordinated Intermediate," <i>Tetrahedron Letters</i> 37(13): 2217-2220, Elsevier Science Ltd. (1996).	
ES	C136	REDDY, K.R. et al., "Stereoselective Synthesis of Nucleoside Monophosphate HepDirect™ Prodrugs," <i>Tetrahedron Letters</i> 46: 4321-4324, Elsevier Ltd. (2005).	
ES	C137	TEN HOEVE, W. and WYNBERG, H. "The Design of Resolving Agents. Chiral Cyclic Phosphoric Acids," <i>J. Org. Chem.</i> 50: 4508-4514, American Chemical Society (1985).	

561118_1.DOC

Examiner Signature	<i>Mark Sackey</i>	Date Considered	9/7/06
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.